Is this the most undervalued FTSE stock?

This FTSE stock has been in the wars since the start of the pandemic, and it can’t seem to buck the trend. Could this be the index’s most undervalued stock?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Smith & Nephew (LSE:SN) is a FTSE 100 stalwart. It currently has a market cap of £8.5bn and it’s one of the most respected medical device manufacturers around the world. However, things haven’t been going to plan for the company and its investors.

While a turnaround is on the corner, is it time we started seeing this hip replacement specialist as a slam dunk bargain?

Share price targets

When I’m looking to assess how much a company should be worth, I often find the best place to start is the share price targets. These are targets created by City and Wall Street analysts, and when compiled into a consensus opinion, they can be incredibly useful.

In the case of Smith & Nephew, we can see that the stock has no ‘Sell’ or ‘Underperform’ ratings. In fact, there are nine ‘Buy’ ratings, four ‘Outperform’ ratings and five ‘Hold’ ratings. That’s a very good sign.

But what’s an even stronger sign is the average share price target, which is currently £13.11. That’s a considerable 34.8% above the current share price. In the current market, I’d suggest we don’t often see stocks that analysts contend to be that undervalued.

Of course, there’s a few caveats here. Firstly, it’s a little lazy just to use other people’s analysis. But secondly, these ratings aren’t always updated that often. This is especially the case for less prominent companies. As such, ratings and share price targets can get outdated. It’s often good practice to discount those published more than three months ago.

Value improving

In February, the medical device giant reported fourth-quarter revenue of $1.46bn, marking a 6.4% increase on an underlying basis. For the year as a whole, the company surpassed expectations with underlying revenue up 7.2%. For 2024, Smith & Nephew remained positive, suggesting further revenue growth in the range of 5% to 6%.

For 2024, analysts are now anticipating the company will deliver earnings per share of 46p. That will rise to 60.3p in 2025, and 73.1p in 2026. That’s 16.7% growth over the medium term. As a result, Smith & Nephew is currently trading at 21 times forward earnings. This then drops to 16 times in 2025, and 13.2 times in 2026.

In turn, that’s a price-to-earnings-to-growth (PEG) ratio of 1.25. If the company didn’t pay a dividend, this PEG ratio would suggest the company is overvalued. But given the 3.4% dividend yield, it’s inconclusive.

P/ESmith & NephewJohnson & JohnsonMedtronic
20242114.316.2
20251613.815.4
202613.213.413.2

It’s always important to compare this data with peers in the same sector, and that’s what I’ve done above. As we can see, towards the end of the forecasting period, Smith & Nephew in trading in line with its peers. It’s also growing faster so could be in better shape.

The bottom line

The advent of effective weight loss drugs has certainly made some analysts wary. After all, obesity is a major reason people need joint replacements. And these drugs have compounded the negative impact of the pandemic on the business.

Nevertheless, I think the long-term picture is positive. There’s certainly enough catalysts in our ageing populations. It might not be the whoppingly undervalued stock that the average share price target suggests, but I certainly think it’s trading below fair value.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Fox has positions in Smith & Nephew Plc. The Motley Fool UK has recommended Smith & Nephew Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

5 steps to start buying shares with under £500

Learn how this writer would start buying shares with a few hundred pounds in a handful of steps, if he…

Read more »

Young happy white woman loading groceries into the back of her car
Investing Articles

The FTSE 100 offers some great bargains. Is this one?

Our writer digs into one FTSE 100 share that has had a rough 2024 to date, ahead of its interim…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£9,000 of savings? Here’s my 3-step approach to aim for £1,794 in passive income

Christopher Ruane walks through the practical steps he would take to try and turn £9,000 into a sizeable passive income…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

I’d buy 29,412 shares of this UK dividend stock for £150 a month in passive income

Insiders have been buying this dividend stock, which offers an 8.5% yield. Roland Head explains why he’d choose the shares…

Read more »

Red briefcase with the words Budget HM Treasury embossed in gold
Investing Articles

Could the new UK budget spell growth for these 6 FTSE stocks? I think so!

Mark David Hartley considers six UK stocks that could enjoy growth off the back of new measures announced in the…

Read more »

Investing Articles

With a 6.6% yield, is now the right time to add this income stock to my ISA?

Our writer’s looking to boost his Stocks and Shares ISA. With this in mind, he’s debating whether to buy a…

Read more »

Dividend Shares

This blue-chip FTSE stock just fell 12.5% in a day. Is it time to consider buying?

Smith & Nephew is a well-known, blue-chip FTSE stock with a decent dividend yield. And its share price just dropped…

Read more »

Investing Articles

At 72p, the Vodafone share price looks to be at least 33% undervalued to me

Our writer looks at a number of valuation measures to determine whether the Vodafone share price reflects the fair value…

Read more »